SCHEMBL377641

SCHEMBL377641

O=C1NC(=O)C(Cc2cnc3cc(OCc4ccccc4)ccc3c2)S1

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 13/20 0.59
PPARA Q07869 6/20 0.54
PPARG P37231 7/20 0.54
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29602962 1.00 FFAR1 (0.59) FFAR1PPARAPPARGCYP3A4
SCHEMBL6956120 0.94 FFAR1 (0.63) FFAR1PPARAPPARG
SCHEMBL6958784 0.93 FFAR1 (0.58) FFAR1PPARAPPARGCYP3A4
SCHEMBL6963885 0.91 FFAR1 (0.53) FFAR1PPARAPPARGCYP3A4
SCHEMBL6964661 0.90 FFAR1 (0.51) FFAR1PPARAPPARGCYP3A4
SCHEMBL6964001 0.90 PPARG (0.56) FFAR1PPARAPPARGCYP3A4
SCHEMBL6959497 0.90 MAOB (0.55) FFAR1PPARAPPARGCYP3A4
SCHEMBL6964875 0.90 FFAR1 (0.61) FFAR1PPARAPPARGCYP3A4
SCHEMBL6955783 0.88 FFAR1 (0.48) FFAR1PPARAPPARGCYP3A4
SCHEMBL6966643 0.87 FFAR1 (0.52) FFAR1PPARAPPARGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338480-B2 Combination treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2012-12-25 US claimed
US-20100292277-A1 COMBINATION TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-11-18 US claimed
EP-2001461-A2 COMBINATION TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2008-12-17 EP claimed
WO-2007117791-A2 COMBINATION TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-10-18 WO claimed
EP-0787725-B1 QUINOLINE DERIVATIVE NIPPON CHEMIPHAR CO (JP) 2003-04-23 EP claimed
US-6121288-A DECREASING VISCERAL FAT, INHIBITING ACCUMULATION OF VISCERAL FAT AND IMPROVING THE DISTRIBUTION OF VISCERAL FAT BY ADMINISTERING A 5-SUBSTITUTED-2,4-THIAZOLIDINEDIONE DERIVATIVE OF GIVEN FORMULA NIPPON CHEMIPHAR CO., LTD. (JP) 2000-09-19 US claimed
EP-0974348-A1 VISCERAL FAT LOWERING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2000-01-26 EP claimed
JP-10182461-A None JP disclosed
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2023-07-06 US disclosed
US-11007162-B2 Methods of reducing small, dense LDL particles CYMABAY THERAPEUTICS, INC. (US) 2021-05-18 US disclosed
US-20190298672-A1 METHODS OF REDUCING SMALL, DENSE LDL PARTICLES CYMABAY THERAPEUTICS, INC. (US) 2019-10-03 US disclosed
US-20190192475-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2019-06-27 US disclosed
EP-2346498-B1 METHODS OF REDUCING SMALL, DENSE LDL PARTICLES CYMABAY THERAPEUTICS INC (US) 2018-12-26 EP disclosed
WO-2002080935-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO disclosed
WO-2000073273-A1 PROCESS FOR THE PREPARATION OF 2-HALO-3-(3-QUINOLYL)PROPIONIC ACID DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2000-12-07 WO disclosed
US-6121288-A DECREASING VISCERAL FAT, INHIBITING ACCUMULATION OF VISCERAL FAT AND IMPROVING THE DISTRIBUTION OF VISCERAL FAT BY ADMINISTERING A 5-SUBSTITUTED-2,4-THIAZOLIDINEDIONE DERIVATIVE OF GIVEN FORMULA NIPPON CHEMIPHAR CO., LTD. (JP) 2000-09-19 US disclosed
EP-0974348-A1 VISCERAL FAT LOWERING AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2000-01-26 EP disclosed
JP-H10182461-A VISCERAL FAT REDUCING AGENT NIPPON CHEMIPHAR CO LTD 1998-07-07 JP disclosed
US-5693651-A HYPOGLYCEMIC AGENTS NIPPON CHEMIPHAR CO., LTD. (JP) 1997-12-02 US disclosed
EP-0787725-A1 QUINOLINE DERIVATIVE NIPPON CHEMIPHAR CO., LTD. (JP) 1997-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190298672-A1 METHODS OF REDUCING SMALL, DENSE LDL PARTICLES LDLR, APOB, HDLBP FFAR1 1151/4885PPARA 123/4885PPARG 409/4885
US-20190192475-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD FFAR1 34/4885PPARA 1/4885PPARG 2/4885
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD FFAR1 34/4885PPARA 1/4885PPARG 2/4885
US-20100292277-A1 COMBINATION TREATMENT OF METABOLIC DISORDERS NR1H3, GPR119, NR1H2 FFAR1 6/4885PPARA 13/4885PPARG 12/4885
US-11007162-B2 Methods of reducing small, dense LDL particles LDLR, APOB, HDLBP FFAR1 1151/4885PPARA 123/4885PPARG 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.